Advertisement

Parvovirus

  • Mridula Sunkara
Chapter

Abstract

Parvovirus B19 is a common infection in young children, and the majority of adults are seropositive. However, congenital parvovirus infection can cause significant morbidity and mortality. Nonimmune pregnant women can acquire parvovirus if exposed to respiratory droplets from infected individuals. If parvovirus reaches the fetus, it can cause significant anemia and, in severe cases, hydrops fetalis. Percutaneous umbilical cord sampling can be used to diagnose and, if necessary, transfuse infected fetuses. Treatment of congenital parvovirus is largely supportive; fetuses who have reached 32 weeks’ gestation or who have severe hydrops should be delivered to allow for aggressive care.

Keywords

Anemia Hydrops fetalis Parvovirus Red blood cells Reticulocytes 

References

  1. 1.
    Rogo LD, Mokhtari-Azad T, Kabir MH, Rezaei F. Human parvovirus B19: a review. Acta Virol. 2014;58:199–213.CrossRefPubMedGoogle Scholar
  2. 2.
    Valentin MN, Cohen PJ. Pediatric parvovirus B19: spectrum of clinical manifestations. Cutis. 2013;92:179–84.PubMedGoogle Scholar
  3. 3.
    Mor O, Ofir I, Pavel R, et al. Parvovirus B19V infection in Israel: prevalence and occurrence of acute infection between 2008 and 2013. Epidemiol Infect. 2016;144:207–14.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Adler SP, Manganello AM, Koch WC, et al. Risk of human parvovirus B19 infections among school and hospital employees during endemic periods. J Infect Dis. 1993;168:361–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Morita E, Sugamura K. Human parvovirus B19-induced cell cycle arrest and apoptosis. Springer Semin Immunopathol. 2002;24:187–99.CrossRefPubMedGoogle Scholar
  6. 6.
    Takahashi T, Ozawa K, Takahashi K, Asano S, Takaku F. Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood. 1990;75:603–10.PubMedGoogle Scholar
  7. 7.
    Barah F, Whiteside S, Batista S, Morris J. Neurological aspects of human parvovirus B19 infection: a systematic review. Rev Med Virol. 2014;24:154–68.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Vigneswaran TV, Brown JR, Breuer J, Burch M. Parvovirus B19 myocarditis in children: an observational study. Arch Dis Child. 2016;101:177–80.CrossRefPubMedGoogle Scholar
  9. 9.
    de Jong EP, Walther FJ, Kroes AC, Oepkes D. Parvovirus B19 infection in pregnancy: new insights and management. Prenat Diagn. 2011;31:419–25.CrossRefPubMedGoogle Scholar
  10. 10.
    Dijkmans AC, de Jong EP, Dijkmans BA, et al. Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications. Curr Opin Obstet Gynecol. 2012;24:95–101.CrossRefPubMedGoogle Scholar
  11. 11.
    Koch WC, Harger JH, Barnstein B, et al. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. Pediatr Infect Dis J. 1998;17:489–94.CrossRefPubMedGoogle Scholar
  12. 12.
    Moise KJ. The usefulness of middle cerebral artery doppler assessment in the treatment of the fetus at risk for anemia. Am J Obstet Gynecol. 2008;18:e1–4.Google Scholar
  13. 13.
    Brown T, Anand A, Ritchie LD, et al. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet. 1984;2:1033–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Al-Buhtori M, Moore L, Benbow EW, Cooper RJ. Viral detection in hydrops fetalis, spontaneous abortion, and unexplained fetal death in utero. J Med Virol. 2011;83:679–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Crane J, Mundle W, Boucoiran I, et al. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 2014;36:1107–16.CrossRefPubMedGoogle Scholar
  16. 16.
    American College of Obstetricians and Gynecologists. Practice bulletin no. 151: cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Obstet Gynecol. 2015;125:1510–25.CrossRefGoogle Scholar
  17. 17.
    Dieck D, Schild RL, Hansmann M, Eis-Hubinger AM. Prenatal diagnosis of congenital parvovirus B19 infection: value of serological and PCR techniques in maternal and fetal serum. Prenat Diagn. 1999;19:1119–23.CrossRefPubMedGoogle Scholar
  18. 18.
    Schild RL, Bald R, Plath H, et al. Intrauterine management of fetal parvovirus B19 infection. Ultrasound Obstet Gynecol. 1999;13:161–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Matsuda H, Sakaguchi K, Shibasaki T, et al. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med. 2005;33:561–3.PubMedGoogle Scholar
  20. 20.
    Lejeune A, Cremer M, von Bernuth H, et al. Persistent pure red cell aplasia in dicygotic twins with persistent congenital parvovirus B19 infection-remission following high dose intravenous immunoglobulin. Eur J Pediatr. 2014;173:1723–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56:968–77.CrossRefPubMedGoogle Scholar
  22. 22.
    Heegarard ED, Hasle H, Skibsted L, Bock J, Brown KE. Congenital anemia caused by parvovirus B19 infection. Pediatr Infect Dis J. 2000;19:1216–8.CrossRefGoogle Scholar
  23. 23.
    Centers for Disease Control and Prevention. Parvovirus B19 and fifth disease. https://www.cdc.gov/parvovirusb19/fifth-disease.html. Accessed 17 Jan 2018.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Neonatology, Department of PediatricsTexas A&M Health Science CenterTempleUSA

Personalised recommendations